Özet:

COVID19 in children may present with a heterogeneous clinical picture. The first serious childhood infection reported in Wuhan, China, started with gastrointestinal symptoms and did not show obvious respiratory symptoms, but quickly progressed to acute respiratory distress syndrome. Respiratory system involvement can range from mild upper respiratory tract symptoms to severe acute respiratory distress syndrome (ARDS). In addition, it has been reported that a multisystem inflammatory syndrome (MIS-C) associated with COVID19 developed in children from England and Italy and then from many countries towards the end of April 2020. MIS-C, which develops in children due to COVID19, is a rare but serious condition associated with COVID19. It is not known whether MIS-C is an infectious immune reaction or a new disease with abnormal development of acquired immunity. The clinical features of MIS-C may be similar to Kawasaki disease and toxic shock syndrome. These include laboratory findings associated with persistent fever, hypotension, gastrointestinal symptoms, rash, myocarditis, and increased inflammation respiratory symptoms may not be present in all cases. Critical pediatric patients such as COVID19-associated septic shock, acute lung injury, need for mechanical ventilation, extracorporeal respiratory and / or circulatory support, acute renal damage, severe MIS-C, Kawasaki disease need to be followed up and treated in the pediatric intensive care unit. In this section, we planned to review the follow-up and treatment of critical COVID19 pediatric patients who may present with different clinical presentations in the pediatric intensive care unit in the light of current literature information.

Anahtar Kelimeler: